Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Definium Therapeutics, Inc. - Common Shares
(NQ:
DFTX
)
34.47
-0.17 (-0.49%)
Delayed Quote
Updated: 4:00 PM EST, Nov 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Definium Therapeutics, Inc. - Common Shares
< Previous
1
2
Next >
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
November 09, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
November 09, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
November 04, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences
November 03, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
October 29, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
October 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
October 13, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
September 28, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
September 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
September 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
September 13, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
September 10, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
September 08, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
August 31, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
August 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
August 17, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
August 12, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 06, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 05, 2026
Issued on behalf of Helus Pharma (Nasdaq: HELP)
From
USA News Group
Via
GlobeNewswire
Definium Therapeutics Announces New Employee Inducement Grants
August 03, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
July 20, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
July 06, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity
From
MarketNewsUpdates.com
Via
GlobeNewswire
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
June 23, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 22, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
